{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T15:43:43Z","timestamp":1770133423457,"version":"3.49.0"},"reference-count":35,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006571","name":"Canterbury District Health Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,3,4]]},"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Actively recruit and intensively follow pregnant women receiving a dose of acellular pertussis vaccine for 4\u2005weeks after vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and settings<\/jats:title>\n                    <jats:p>A prospective observational study conducted in 2 New Zealand regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Women in their 28th\u201338th week of pregnancy, recruited from primary care and antenatal clinics at the time of Tdap administration. Telephone interviews were conducted at 48\u2005h and 4\u2005weeks postvaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes measures<\/jats:title>\n                    <jats:p>Outcomes were injection site reactions, systemic symptoms and serious adverse events (SAEs). Where available, data have been classified and reported according to Brighton Collaboration definitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>793 women participated with 27.9% receiving trivalent inactivated influenza vaccine concomitantly. 79% of participants reported mild or moderate pain and 2.6% severe pain. Any swelling was reported by 7.6%, induration by 12.0% (collected from 1 site only, n=326), and erythema by 5.8% of participants. Fever was reported by 17 (2.1%) participants, 14 of these occurred within 24\u2005h. Headache, dizziness, nausea, myalgia or arthralgia was reported by &lt;4% of participants, respectively, and fatigue by 8.4%. During the study period, there were 115 adverse events in 113 participants, most of which were minor. At the end of the reporting period, 31 events were classified as serious (eg, obstetric bleeding, hypertension, infection, tachycardia, preterm labour, exacerbation of pre-existing condition and pre-eclampsia). All had variable onset time from vaccination. There were two perinatal deaths. Clinician assessment of all SAEs found none likely to be vaccine related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vaccination with Tdap in pregnant women was well tolerated with no SAE likely to be caused by the vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12613001045707.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010911","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T23:13:40Z","timestamp":1461021220000},"page":"e010911","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":39,"title":["Safety of Tdap vaccine in pregnant women: an observational study"],"prefix":"10.1136","volume":"6","author":[{"given":"Helen","family":"Petousis-Harris","sequence":"first","affiliation":[{"name":"Department of General Practice and Primary Health Care, Immunisation Advisory Centre, The University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Walls","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Otago, Christchurch, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of General Practice and Primary Health Care, Immunisation Advisory Centre, The University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Paynter","sequence":"additional","affiliation":[{"name":"Department of General Practice and Primary Health Care, Immunisation Advisory Centre, The University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Graham","sequence":"additional","affiliation":[{"name":"Canterbury District Health Board, Christchurch, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikki","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of General Practice and Primary Health Care, Immunisation Advisory Centre, The University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,4,18]]},"reference":[{"key":"2025121600231197000_6.4.e010911.1","unstructured":"Advisory Committee on Immunization Practices (ACIP). Summary Report February 23\u201324, 2011. Atlanta, Georgia, 2011."},{"key":"2025121600231197000_6.4.e010911.2","unstructured":"Davies SC . Temporary programme of pertussis (whooping cough) vaccination of pregnant women. 28 Sept 2012. Department of Health, London, 2012."},{"key":"2025121600231197000_6.4.e010911.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60686-3"},{"key":"2025121600231197000_6.4.e010911.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu821"},{"key":"2025121600231197000_6.4.e010911.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.084"},{"key":"2025121600231197000_6.4.e010911.6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/AOG.0000000000001066","article-title":"Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy","volume":"126","author":"Sukumaran","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2025121600231197000_6.4.e010911.7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/AOG.0000000000000862","article-title":"Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination","volume":"125","author":"Morgan","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2025121600231197000_6.4.e010911.8","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1016\/j.vaccine.2015.04.097","article-title":"Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System","volume":"33","author":"Datwani","year":"2015","journal-title":"Vaccine"},{"key":"2025121600231197000_6.4.e010911.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.14825"},{"key":"2025121600231197000_6.4.e010911.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4219"},{"key":"2025121600231197000_6.4.e010911.11","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1072664"},{"key":"2025121600231197000_6.4.e010911.12","unstructured":"Ministry of Health. Processes for safe immunisation. In: Ministry of Health , ed. Immunisation Handbook 2014. Wellington: Ministry of Health, 2014:75."},{"key":"2025121600231197000_6.4.e010911.13","unstructured":"International Conference on Harmonisation. Clinical safety data management: definitions and standards for expedited reporting E2A. International Conference on Harmonisation; 1994."},{"key":"2025121600231197000_6.4.e010911.14","unstructured":"International Conference on Harmonisation. Post-approval safety data management: definitions and standards for expedited reporting E2D. International Conference on Harmonisation; 2003."},{"key":"2025121600231197000_6.4.e010911.15","unstructured":"Working Group on Vaccine Pharmacovigilance. Definition and application of terms for vaccine pharmacovigilance. Geneva, Switzerland: World Health Organization, 2012."},{"key":"2025121600231197000_6.4.e010911.16","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2008.10.006","article-title":"A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"26","author":"Gidudu","year":"2008","journal-title":"Vaccine"},{"key":"2025121600231197000_6.4.e010911.17","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1016\/j.vaccine.2007.04.056","article-title":"Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data","volume":"25","author":"Kohl","year":"2007","journal-title":"Vaccine"},{"key":"2025121600231197000_6.4.e010911.18","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1016\/j.vaccine.2007.04.062","article-title":"Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Kohl","year":"2007","journal-title":"Vaccine"},{"key":"2025121600231197000_6.4.e010911.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.09.007"},{"key":"2025121600231197000_6.4.e010911.20","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1080\/21645515.2015.1016670","article-title":"Factors associated with reported pain on injection and reactogenicity to an OMV meningococcal B vaccine in children and adolescents","volume":"11","author":"Petousis-Harris","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2025121600231197000_6.4.e010911.21","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1016\/j.vaccine.2012.05.052","article-title":"Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance","volume":"30","author":"Petousis-Harris","year":"2012","journal-title":"Vaccine"},{"key":"2025121600231197000_6.4.e010911.22","unstructured":"Perinatal and Maternal Mortality Review Committee. Eighth annual report of the perinatal and maternal mortality review committee. Reporting mortality 2012. Wellington, 2014."},{"key":"2025121600231197000_6.4.e010911.23","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2165\/11209630-000000000-00000","article-title":"Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (boostrix \u00ae): a review of its properties and use as a single-dose booster immunization","volume":"72","author":"McCormack","year":"2012","journal-title":"Drugs"},{"key":"2025121600231197000_6.4.e010911.24","first-page":"502","article-title":"[Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults]","volume":"130","author":"Abarca","year":"2002","journal-title":"Rev Med Chil"},{"key":"2025121600231197000_6.4.e010911.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.028"},{"key":"2025121600231197000_6.4.e010911.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.vaccine.2010.10.025","article-title":"A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix\u2122) is immunogenic and well tolerated in adults","volume":"29","author":"Booy","year":"2010","journal-title":"Vaccine"},{"key":"2025121600231197000_6.4.e010911.27","first-page":"286","article-title":"Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults","volume":"47","author":"Chan","year":"2006","journal-title":"Singapore Med J"},{"key":"2025121600231197000_6.4.e010911.28","doi-asserted-by":"publisher","DOI":"10.1086\/655825"},{"key":"2025121600231197000_6.4.e010911.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00252-8"},{"key":"2025121600231197000_6.4.e010911.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00568-X"},{"key":"2025121600231197000_6.4.e010911.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3633"},{"key":"2025121600231197000_6.4.e010911.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.03.032"},{"key":"2025121600231197000_6.4.e010911.33","unstructured":"Ministry of Health. New Zealand Maternity Clinical Indicators 2013. Wellington: Ministry of Health, 2015."},{"key":"2025121600231197000_6.4.e010911.34","unstructured":"Ministry of Health. Hospital-based Maternity Events 2007. Wellington: Ministry of Health, 2010."},{"key":"2025121600231197000_6.4.e010911.35","doi-asserted-by":"crossref","first-page":"59.e1","DOI":"10.1016\/j.ajog.2012.05.006","article-title":"Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women","volume":"207","author":"Zheteyeva","year":"2012","journal-title":"Am J Obstet Gynecol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:23:20Z","timestamp":1765873400000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,18]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1136\/bmjopen-2015-010911"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010911","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}